Supernus Pharmaceuticals ... (SUPN)
NASDAQ: SUPN
· Real-Time Price · USD
49.27
0.05 (0.10%)
At close: Oct 15, 2025, 3:59 PM
49.27
0.00%
After-hours: Oct 15, 2025, 04:10 PM EDT
Supernus Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 661.82M | 607.52M | 667.24M | 579.77M |
Cost of Revenue | 77.91M | 83.78M | 87.22M | 75.06M |
Gross Profit | 583.91M | 523.74M | 580.02M | 504.71M |
Operating Income | 81.67M | -5.27M | 67.3M | 86.03M |
Interest Income | 16.2M | 10.45M | 21.69M | 10.57M |
Pretax Income | 97.87M | 2.77M | 60.74M | 73.17M |
Net Income | 73.86M | 1.32M | 60.71M | 53.42M |
Selling & General & Admin | 321.58M | 336.36M | 377.22M | 304.76M |
Research & Development | 108.8M | 91.59M | 74.55M | 90.47M |
Other Expenses | 71.87M | 101.06M | 82.63M | 29.99M |
Operating Expenses | 502.25M | 529.01M | 534.4M | 425.21M |
Interest Expense | n/a | 2.42M | 7.07M | 23.42M |
Selling & Marketing Expenses | 88.5M | 99.7M | 267.79M | 199.71M |
Cost & Expenses | 580.15M | 612.79M | 621.62M | 500.28M |
Income Tax Expense | 24M | 1.45M | 32K | 19.75M |
Shares Outstanding (Basic) | 55.1M | 54.54M | 53.67M | 53.1M |
Shares Outstanding (Diluted) | 55.96M | 55.51M | 61.68M | 54.36M |
EPS (Basic) | 1.34 | 0.02 | 1.13 | 1.01 |
EPS (Diluted) | 1.32 | 0.02 | 1.04 | 0.98 |
EBITDA | 178.28M | 90.04M | 153.44M | 129.19M |
EBIT | 97.87M | 5.18M | 67.81M | 96.6M |
Depreciation & Amortization | 80.41M | 84.86M | 85.63M | 32.59M |
Source: Financial Modeling Prep. Financial Sources.